Patients with stage IIIB/IV disease stratified by adjuvant therapy and gender were randomised 1 : 1 to axitinib ( 5 mg twice daily ) or bevacizumab [ 15 mg/kg every 3 weeks ( Q3W ) ] , both with paclitaxel ( 200 mg/m ( 2 ) Q3W ) / carboplatin ( AUC 6 mg min/ml Q3W ) .